Simplified recombinant plasmin: Production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin

Thrombosis and Haemostasis

Volumn 100, Issue 3, 2008, Pages 413-419

  Hunt, Jennifer A ^a   Petteway Jr , Stephen R ^a   Scuderi, Philip ^a   Novokhatny, Valery ^a  

^a Talecris Biotherapeutics Inc   (United States)

Author keywords

Fibrinolysis; Peripheral arterial occlusion; Plasmin; Plasminogen; Thrombosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALPHA 2 MACROGLOBULIN; AMINOCAPROIC ACID DERIVATIVE; ENZYME PRECURSOR; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMIN; RECOMBINANT PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; SEPHAROSE; SERINE PROTEINASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE;

AMINO ACID SEQUENCE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DRUG POTENCY; ENZYME ACTIVATION; FIBRINOLYSIS; GENE DELETION; HUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PURIFICATION;

AMINO ACID SEQUENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESCHERICHIA COLI; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PLASMA; PLASMIN; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SPECTROMETRY, FLUORESCENCE; TIME FACTORS; URINARY PLASMINOGEN ACTIVATOR;

EID: 51349103793     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH08-04-0225     Document Type: Article

References (36)

1. Alesh I, Kayali F, Stein PD. Catheter-directed thrombolysis (intrathrombus injection) in treatment of deep venous thrombosis: a systematic review. Catheter Cardiovasc Interv 2007; 70: 143-148.
2. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000; 31: S1-S296.
3. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Associations for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006; 47: 1239-1312.
4. Semba CP, Bakal CW, Calis KA, et al, and the Advisory Panel on Catheter-Directed Thrombolytic Therapy. Alteplase as an alternative to urokinase. J Vasc Interv Radiol 2000; 11: 279-287.
5. Shlansky-Goldberg R, Baumbach G, Marder V. A phase I trial of locally-delivered human plasmin to evaluate safety and thrombolytic efficacy in patients with hemodialysis graft occlusion (HGO). Presented at 21st Congress of the International Society on Thrombosis and Haemostasis 2007; Geneva, Switzerland: Abstract P-S-385.
6. Ponting CP, Marshall JM, Cederholm-Williams SA. Plasminogen: a structural review. Blood Coagul Fibrinolysis 1992; 3: 605-614.
7. Lerch PG, Rickli EE, Lergier W, et al. Localization of individual lysine-binding regions in human plasminogen and investigations on their complex-forming properties. Eur J Biochem 1980; 107: 7-13.
8. Markus G, DePasquale JL, Wissler FC. Quantitative determination of the binding of ε-aminocaproic acid to native plasminogen. J Biol Chem 1978; 253: 727-732.
9. Derbise A, Song YP, Parikh S, et al. Role of the C-terminal lysine residues of streptococcal surface enolase in Glu- and Lys-plasminogen-binding activities of group A streptococci. Infect Immun 2004; 72: 94-105.
10. Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem 1988; 263: 11928-11934.
11. Pancholi V, Fischetti VA. α-Enolase, a novel strong plasmin(ogen) binding protein on the surface of pathogenic streptococci. J Biol Chem 1998; 273: 14503-14515.
12. Wistedt AC, Kotarsky H, Marti D, et al. Kringle 2 mediates high affinity binding of plasminogen to an internal sequence in streptococcal surface protein PAM. J Biol Chem 1998; 273: 24420-24424.
13. Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin and fibrinogen. J Biol Chem 1983; 258: 4249-4256.
14. Wu H-L, Chang B-I, Wu D-H, et al. Interaction of plasminogen and fibrin in plasminogen activation. J Biol Chem 1990; 265: 19658-19664.
15. Wiman B, Lijnen HR, Collen D. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen. Biochim Biophys Acta 1979; 579: 142-154.
16. Wu T-P, Padmanabhan KP, Tulinsky A. The structure of recombinant plasminogen kringle 1 and the fibrin binding site. Blood Coagul Fibrinolysis 1994; 5: 157-166.
17. Busby SJ, Mulvihill E, Rao D, et al. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. J Biol Chem 1991; 266: 15286-15292.
18. Marder VJ, Landskroner K, Novokhatny V, et al. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost 2001; 86: 739-745.
19. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost 2003; 1: 1034-1041.
20. 2-antiplasmin. Biochem J 1980; 191: 229-232.
21. 2-macroglobulin. Biochem J 1978; 171: 27-38.
22. Matsuka YV, Novokhatny VV, Kudinov SA. Fluorescence spectroscopic analysis of ligand binding to kringle 1 + 2 + 3 and kringle 1 fragments from human plasminogen. Eur J Biochem 1990; 190: 93-97.
23. Douglas JT, von Haller PD, Gehrmann M, et al. The two-domain NK1 fragment of plasminogen: folding, ligand binding, and thermal stability profile. Biochemistry 2002; 41: 3302-3310.
24. Wohl RC, Summaria L, Robbins KC. Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37°C. J Biol Chem 1980; 255: 2005-2013.
25. Christensen U, Sottrup-Jensen L, Magnusson S, et al. Enzymic properties of the neo-plasmin-Val-422 (miniplasmin). Biochim Biophys Acta 1979; 567: 472-481.
26. Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Biochem 1978; 84: 573-578.
27. 2-macroglobulin, and antithrombin III in the presence of heparin. Thromb Res 1990; 59: 449-462.
28. Castellino FJ, Davidson DJ, Rosen E, et al. Expression of human plasminogen cDNA in lepidopteran insect cells and analysis of asparagine-linked glycosylation patterns of recombinant plasminogens. Methods Enzymol 1993; 223: 168-185.
29. Shi G-Y, Wu H-L. Isolation and characterization of microplasminogen. A low molecular weight form of plasminogen. J Biol Chem 1988; 263: 17071-17075.
30. Wang J, Reich E. Structure and function of microplasminogen: II. Determinants of activation by urokinase and by the bacterial activator streptokinase. Protein Sci 1995; 4: 1768-1779.
31. Deitcher SR, Funk WD, Buchanan J, et al. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 2006; 6: 1361-1369.
32. Moll S, Kenyon P, Bertoli L, et al. Phase II trial of alfimeprase, a novel-acting fibrin degradation agent, for occluded central venous access devices. J Clin Oncol 2006; 24: 3056-3060.
33. Ouriel K, Cynamon J, Weaver FA, et al. A phase I trial of alfimeprase for peripheral arterial thrombolysis. J Vasc Interv Radiol 2005; 16: 1075-1083.
34. ThromboGenics NV. ThromboGenics NV announces update on its microplasmin development strategy for peripheral vascular disease. Available at: http://www.thrombogenics.com/documents/06_TG_10PAOD_DVTENGFINAL.pdf. Last accessed March 14, 2008.
35. Gonias SL, Figler NL. Alpha 2-macroglobulin is the primary inhibitor of miniplasmin in vitro and in vivo in the mouse. Comparison with alpha 2-antiplasmin in simultaneous reaction experiments. Biochem J 1988; 255: 725-730.
36. Shah AR, Scher L. Drug evaluation: alfimeprase, a plasminogen-independent thrombolytic. IDrugs 2007; 10: 329-335.